Prana Thoracic, a Houston, TX-based medtech startup which specializes in lung cancer intervention, raised $3M in Series A extension.
The round, which brought the total funding to $9M, was led by cultivate(MD), GenHenn Capital, and Houston Angel Network, with participation from prior lead investor New World Angels. Existing funders included Johnson & Johnson Development Corp, Texas Medical Center Venture Fund, and the Cancer Prevention & Research Institute of Texas (CPRIT).
The company intends to use the funds to accelerate product development and to advance through its clinical and regulatory plans.
Led by CEO Joanna Nathan, Prana Thoracic was founded with a vision to transform lung cancer intervention through precision surgical solutions. It aims to right-size interventions for those patients seeking earlier options in the management of their disease. Its flagship product, the Prana System, has been designed to enable image-guided, minimally invasive surgery, conserving healthy tissue and driving personalized treatment plans in a range of conditions including lung cancer.